Non-motor symptoms (NMS) are an important and ubiquitous determinant of quality of life in Parkinson’s disease (PD). However, robust evidence for their treatment is still…
Read More
Neurodegenerative and psychiatric disorders (NPDs) confer a huge health burden, which is set to increase as populations age. New, remotely delivered diagnostic assessments that can…
Dr Daniel van Wamelen, Dr Dhaval Trivedi and Prof K Ray Chaudhuri of the EUROPAR team have published an exciting new article on remote technologies…
People with Parkinson’s Disease (PwP) may be at higher risk for complications from the Coronavirus Disease 2019 (Covid-19) due to older age and to the…
Frailty is recognized as a clinical condition associated with increased vulnerability for developing negative health outcomes but has been little studied in patients with Parkinson’s disease (PD). Here,…
Rapid eye movement (REM) sleep behaviour disorder (RBD) is a REM parasomnia that often predicts the later occurrence of alpha-synucleinopathies. Variants in the gene encoding…
The unmet timely diagnosis requirements, that take place years after substantial neural loss and neuroperturbations in neuropsychiatric disorders, affirm the dire need for biomarkers with…
Twenty-four-hour treatment options could provide a continuous drug delivery strategy in advanced Parkinson’s disease and can ameliorate motor and non-motor complications. Use of levodopa infusion…
Sleep is crucial to wellness, but it is disrupted in almost all patients with Parkinson’s disease. Many factors can cause disturbed sleep in people with…
Non-motor symptoms (NMSs) are highly prevalent throughout the course of Parkinson’s disease (PD). Pain, autonomic dysfunction and sleep disturbances remain at the forefront of the…
